Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax MSTR Option Income Strategy ETF vs Sana Biotechnology Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $13.56, while Sana Biotechnology Inc trades at $3.17 (market cap $873.84M). The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| MSTY | SANA | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $108.80 | $5.92 |
52-Week Low | $11.55 | $2.68 |
Market Cap | — | $873.84M |
Enterprise Value | — | $848.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTY trades at $13.12, up 2.34% today but remains in a bearish technical trend with significant price erosion over the past six months. The ETF generates weekly distributions but has experienced substantial capital depreciation, with a $10,000 investment in January 2026 declining to approximately $6,614 by July 2026. Technical indicators show bearish momentum with resistance at $14 and support at $12, while fundamental valuation metrics remain unavailable for analysis.
The outlook remains challenging as MSTY's covered-call strategy caps upside potential while exposing investors to full downside risk. Despite high distribution yields, the structural limitations and dependence on underlying MSTR volatility create significant investment risks. Investors face uncapped losses despite regular payouts, with media coverage highlighting concerns about the ETF's long-term sustainability.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
